The global economy is heading towards a double dip phenomenon. The scenario is not very conducive for high-end capital equipments such as PET and SPECT scanners. This is delaying the purchase of new equipments and boosting the market for refurbished instruments.

Increasing awareness among the physicians with respect to nuclear imaging techniques, mounting application areas such as neurological diseases, and rising cases in oncology are driving the PET and SPECT imaging market.

Increasing aging population and widening applications of PET and SPECT imaging due to continuous developments and discovery of new radiopharmaceuticals are predominantly driving the diagnostic imaging market.

The emerging trend catching interest of the players is fusion of nuclear imaging with different modalities of diagnostic imaging products. The merging of imaging modalities such as PET/CT, SPECT/CT, and MRI/PET helps in providing full gamut of imaging scans through the same unit and at the same time. Further, portable diagnostic equipment are facing an immense demand from physicians.

PET is more preferred as compared to SPECT imaging as PET provides higher resolution images, and the lack of availability of technetium-99m for SPECT is forcing the medical community and the industry to look for alternatives. On the other hand, the high cost of PET restricts its use in cost sensitive markets.

PET is predominately used in oncology as the quality of image provided gives more comprehensive information about the tumor. SPECT, on the other hand, holds 90% share in cardiology. PET is catching up with new radiopharmaceuticals, specifically for cardiac PET.

The U.S. accounts for the highest share of the global PET and SPECT market; followed by Europe. Asia-Pacific (excluding Japan) stands third. The growth in the medical device industry has been spurred by Asian economies (China and India) and a few countries of South America (Brazil and Peru). Rest of the world is still lagging behind in nuclear imaging market.

Aging population and increase in the chronic disease population are considered as the main drivers of the PET and SPECT market in the developed nations and rising fiscal deficit and economic recession are expected to inhibit the growth of the developed nations.

The PET and SPECT market is highly consolidated with most of it being held by a few major players. GE Healthcare (U.K.), Philips (The Netherlands), and Siemens (Germany) together constitute above 85% of the market. GE Healthcare is a leading player due to better accompanying services along with the products. The other players trying to make an entry into the niche market are Positron Corporation (U.S), Spectrum (U.S), and Naviscan (U.S).

Scope of the report

Global PET and SPECT imaging market research report evaluates the global market of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) imaging with respect to the product and application market. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

• PET
• PET/CT
• SPECT
• SPECT/CT

PET and SPECT market is also considered by the types of applications:

• Oncology
• Cardiology
• Neurology

The geographies covered under the report are

• North America
• Europe
• Asia-Pacific (excluding Japan)
• Japan
• Rest of the World

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. The report does provide market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings and future forecasts in minds.

TABLE OF CONTENTS 
 
1 INTRODUCTION
  1.1 KEY TAKE-AWAYS
  1.2 REPORT DESCRIPTION
  1.3 MARKETS COVERED
  1.4 STAKEHOLDERS
  1.5 RESEARCH METHODOLOGY
      1.5.1 MARKET SIZE
      1.5.2 MARKET SHARE
      1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
      1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
      1.5.5 ASSUMPTIONS
 
2 EXECUTIVE SUMMARY
 
3 MARKET OVERVIEW
  3.1 INTRODUCTION
  3.2 EVOLUTION OF PET & SPECT TECHNOLOGY
      3.2.1 EVOLUTION OF PET
            3.2.1.1 Challenges in early stages
            3.2.1.2 Concerted efforts to resolve concerns of infrastructure & finance
                    3.2.1.2.1 Facilities to purchase patient-specific doses
                    3.2.1.2.2 Limited financial risk for hospitals
      3.2.2 EVOLUTION OF SPECT
  3.3 DIFFERENCE BETWEEN PET & SPECT
  3.4 HYBRID IMAGING VS STANDALONE MODULES
  3.5 END-USER ANALYSIS
  3.6 MARKET DYNAMICS
      3.6.1 DRIVERS & RESTRAINTS
            3.6.1.1 Rising incidence of cancer & cardiac diseases to push the sales of scanners
            3.6.1.2 Approval of florbetapir to increase the sales of scanners
            3.6.1.3 Greater accuracy & insights of the diseases compared to other diagnostic methods
            3.6.1.4 Economic downturn to affect the overall PET-SPECT market
      3.6.2 OPPORTUNITIES
            3.6.2.1 Untapped market of emerging countries
            3.6.2.2 Non-linear fusion capability allows manipulations for better image quality
  3.7 TRENDS
  3.8 WINNING IMPERATIVES
      3.8.1 LAUNCH OF APPLICATION DEDICATED SCANNERS
  3.9 BURNING ISSUES
      3.9.1 U.S. HEALTHCARE REFORM
      3.9.2 LACK OF RAW MATERIALS FOR SPECT
      3.9.3 PET/MRI
  3.10 EMERGING MARKETS FOR PET
  3.11 EMERGING THERAPEUTIC USES OF PET
  3.12 LOW-COST PRODUCTION CENTERS TO LOWER PRICE -TAG
      3.12.1 GE HEALTHCARE FOCUSING ON INDIA
      3.12.2 POSITRON CORPORATION’S JV WITH CHINESE COMPANY
      3.12.3 SIEMENS HEALTHCARE TAPPING MARKET IN EMERGING COUNTRIES
  3.13 MARKET SHARE ANALYSIS
      3.13.1 BY KEY PLAYERS
      3.13.2 BY TECHNOLOGY
      3.13.3 BY APPLICATIONS
 
4 PET & SPECT MARKET, BY TECHNOLOGY
  4.1 PET
      4.1.1 DRIVERS & RESTRAINTS
            4.1.1.1 Adequate FDG supply to augment PET scanner market
            4.1.1.2 Enhanced reimbursement scenario for PET in U.S. to improve prospects of sales
            4.1.1.3 Availability of various radioisotopes for organ specific scans will drive future growth
            4.1.1.4 Lack of infrastructure - a major lacuna
  4.2 STANDALONE PET
      4.2.1 DRIVERS & RESTRAINTS
            4.2.1.1 Increase in cardiovascular disease incidences to increase the use of PET scanners
            4.2.1.2 Dominance of hybrid PET/CT to hamper standalone PET sales
  4.3 HYBRID PET TECHNOLOGY
      4.3.1 PET/CT
            4.3.1.1 Drivers and opportunities
                    4.3.1.1.1 Continuous improvement in PET/CT product lines support growth in revenue
                    4.3.1.1.2 Role of PET/CT in treatment planning to leverage growth
                    4.3.1.1.3 Development of mobile scanners will drive sales in the nuclear imaging market
      4.3.2 PET/MRI
            4.3.2.1 Superior imaging compared to CT in neurological studies
  4.4 SPECT
      4.4.1 DRIVERS & RESTRAINTS
            4.4.1.1 Low-cost radionuclides to favor the growth of SPECT
            4.4.1.2 Affordability to drive the sales of SPECT
            4.4.1.3 Lack of availability of Technetium-99m to affect the SPECT market
  4.5 STANDALONE SPECT
      4.5.1 DRIVERS & RESTRAINTS
            4.5.1.1 Detection to evaluation of treatment of neurological diseases drives standalone SPECT market
            4.5.1.2 Improved treatment for cardiovascular diseases will lead to increased SPECT sales
            4.5.1.3 Low spatial resolution & absence of anatomical data - a negative factor
  4.6 SPECT/CT
      4.6.1 DRIVERS
            4.6.1.1 Advanced technology like Siemens’ IQ.SPECT to improve image quality and thus sales
            4.6.1.2 Niche application like neuroendocrine tumor imaging to be one of the major factors to drive SPECT/CT sales
 
5 PET & SPECT MARKET, BY APPLICATIONS
  5.1 INTRODUCTION
  5.2 ONCOLOGY
  5.3 CARDIOLOGY
  5.4 NEUROLOGY

6 GEOGRAPHICAL ANALYSIS
  6.1 INTRODUCTION
  6.2 U.S. PET-SPECT MARKET
  6.3 EUROPE PET-SPECT MARKET
  6.4 APAC PET-SPECT MARKET
  6.5 JAPAN PET-SPECT MARKET
  6.6 ROW PET-SPECT MARKET
 
7 COMPETITIVE LANDSCAPE
  7.1 COMPETITIVE STRUCTURE
 
8 COMPANY PROFILES
  8.1 AGFA-GEVAERT N.V.
      8.1.1 OVERVIEW
      8.1.2 PRODUCTS & SERVICES
      8.1.3 FINANCIALS
      8.1.4 STRATEGY
      8.1.5 DEVELOPMENTS
  8.2 CARDIARC LTD
      8.2.1 OVERVIEW
      8.2.2 PRODUCTS & SERVICES
      8.2.3 FINANCIALS
      8.2.4 STRATEGY
      8.2.5 DEVELOPMENTS
  8.3 COVIDIEN PLC
      8.3.1 OVERVIEW
      8.3.2 PRODUCTS & SERVICES
      8.3.3 FINANCIALS
      8.3.4 STRATEGY
      8.3.5 DEVELOPMENTS
  8.4 DIGIRAD CORPORATION
      8.4.1 OVERVIEW
      8.4.2 PRODUCTS & SERVICES
      8.4.3 FINANCIALS
      8.4.4 STRATEGY
      8.4.5 DEVELOPMENTS
  8.5 GAMMA MEDICA INC
      8.5.1 OVERVIEW
      8.5.2 PRODUCTS & SERVICES
      8.5.3 FINANCIALS
      8.5.4 STRATEGY
      8.5.5 DEVELOPMENTS
  8.6 GE HEALTHCARE
      8.6.1 OVERVIEW
      8.6.2 PRODUCTS & SERVICES
      8.6.3 FINANCIALS
      8.6.4 STRATEGY
      8.6.5 DEVELOPMENTS
  8.7 HOLOGIC INC.
      8.7.1 OVERVIEW
      8.7.2 PRODUCTS & SERVICES
      8.7.3 FINANCIALS
      8.7.4 STRATEGY
      8.7.5 DEVELOPMENTS
  8.8 MEDX INC
      8.8.1 OVERVIEW
      8.8.2 PRODUCTS & SERVICES
      8.8.3 FINANCIALS
      8.8.4 STRATEGY
      8.8.5 DEVELOPMENTS
  8.9 NAVISCAN INC
      8.9.1 OVERVIEW
      8.9.2 PRODUCTS & SERVICES
      8.9.3 FINANCIALS
      8.9.4 STRATEGY
      8.9.5 DEVELOPMENTS
  8.10 POSITRON CORPORATION
      8.10.1 OVERVIEW
      8.10.2 PRODUCTS & SERVICES
      8.10.3 FINANCIALS
      8.10.4 STRATEGY
      8.10.5 DEVELOPMENTS
  8.11 ROYAL PHILIPS ELECTRONICS
      8.11.1 OVERVIEW
      8.11.2 PRODUCTS & SERVICES
      8.11.3 FINANCIALS
      8.11.4 STRATEGY
      8.11.5 DEVELOPMENTS
  8.12 SEGAMI CORPORATION
      8.12.1 OVERVIEW
      8.12.2 PRODUCTS & SERVICES
      8.12.3 FINANCIALS
      8.12.4 STRATEGY
      8.12.5 DEVELOPMENTS
  8.13 SIEMENS HEALTHCARE
      8.13.1 OVERVIEW
      8.13.2 PRODUCTS & SERVICES
      8.13.3 FINANCIALS
      8.13.4 STRATEGY
      8.13.5 DEVELOPMENTS
  8.14 SPECTRUM DYNAMICS LTD
      8.14.1 OVERVIEW
      8.14.2 PRODUCTS & SERVICES
      8.14.3 FINANCIALS
      8.14.4 STRATEGY
      8.14.5 DEVELOPMENTS 
  
 
LIST OF TABLES 
 
TABLE 1 GLOBAL PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 2 GLOBAL PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS)
TABLE 3 WINNING IMPERATIVES FOR PET-SPECT MARKET
TABLE 4 INVESTMENT IN PET, BY COMPANY
TABLE 5 GLOBAL PET MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 6 PET MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION)
TABLE 7 GLOBAL PET INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS)
TABLE 8 PET INSTALLATIONS, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS)
TABLE 9 STANDALONE PET MARKET, BY GEOGRAPHY, 2009 – 2016 ($MILLION)
TABLE 10 STANDALONE PET INSTALLATIONS, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS)
TABLE 11 PET/CT MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION)
TABLE 12 PET/CT INSTALLATIONS, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS)
TABLE 13 GLOBAL SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 14 SPECT MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION)
TABLE 15 GLOBAL SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS) 
TABLE 16 SPECT INSTALLATIONS, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS)
TABLE 17 STANDALONE SPECT MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION)
TABLE 18 STANDALONE SPECT INSTALLATIONS, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS)
TABLE 19 SPECT/CT MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION)
TABLE 20 SPECT/CT INSTALLATIONS, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS) 
TABLE 21 GLOBAL PET MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($MILLION)
TABLE 22 GLOBAL SPECT MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($MILLION)
TABLE 23 GLOBAL ONCOLOGY MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 24 GLOBAL CARDIOLOGY MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION) 
TABLE 25 GLOBAL NEUROLOGY MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION) 
TABLE 26 PET-SPECT MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION)
TABLE 27 PET-SPECT INSTALLATIONS, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS) 
TABLE 28 U.S: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 29 U.S: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS) 
TABLE 30 EUROPE: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 31 EUROPE: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS)
TABLE 32 APAC: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 33 APAC: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS)
TABLE 34 JAPAN: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 35 JAPAN: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS)
TABLE 36 ROW: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION)
TABLE 37 ROW: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 – 2016 (NO. OF UNITS) 
TABLE 38 MERGERS & ACQUISITIONS, 2008 –2011
TABLE 39 NEW PRODUCTS DEVELOPMENT, 2008 – 2011
TABLE 40 AGREEMENTS & COLLABORATIONS, 2008 – 2011
TABLE 41 OTHER DEVELOPMENTS, 2008 – 2011
TABLE 42 AGFA-GEVAERT N.V.: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 43 AGFA-GEVAERT N.V.: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 44 AGFA-GEVAERT N.V.: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 45 COVIDIEN PLC.: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 46 COVIDIEN PLC.: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 47 COVIDIEN PLC.: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 48 DIGIRAD CORPORATION: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 49 DIGIRAD CORPORATION: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 50 GE HEALTHCARE: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 51 GE HEALTHCARE: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 52 GE HEALTHCARE: TECHNOLOGY INFRASTRUCTURE MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($BILLION)
TABLE 53 GE HEALTHCARE: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($BILLION)
TABLE 54 HOLOGIC INC: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 55 HOLOGIC INC: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 56 POSITRON CORPORATION: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 57 PHILIPS ELECTRONICS: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 58 PHILIPS ELECTRONICS: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 59 PHILIPS ELECTRONICS: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 60 SIEMENS: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 61 SIEMENS: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 62 SIEMENS: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
 
 
LIST OF FIGURES 
 
FIGURE 1 EVOLUTION OF PET
FIGURE 2 EVOLUTION OF SPECT
FIGURE 3 PET VS SPECT
FIGURE 4 GLOBAL MARKET SHARE OF PET & SPECT END-USERS (2003 VS 2010)
FIGURE 5 MARKET DYNAMICS OF PET-SPECT MARKET
FIGURE 6 EVALUATION OF EMERGING COUNTRIES IN MARKET COMPETITIVENESS
FIGURE 7 EMERGING THERAPEUTIC USES OF PET
FIGURE 8 GLOBAL PET-SPECT MARKET REVENUE, BY KEY PLAYERS, 2011
FIGURE 9 GLOBAL PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2011
FIGURE 10 GLOBAL PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2011
FIGURE 11 GLOBAL PET-SPECT MARKET REVENUE, BY APPLICATIONS, 2011
FIGURE 12 POTENTIAL CLINICAL APPLICATIONS OF PET/MRI
FIGURE 13 STRATEGIC DEVELOPMENTS, 2008 – 2011

Global PET and SPECT Equipment Market

This study analyses the competitive scenario of the world PET and SPECT imaging market and the strategies employed by the key industry players to develop products and services.

The number of installations is high for SPECT due to the lower cost. The installation market is expected to grow at a CAGR of 4.7% from 2011 to 2016. There is continuous development in technology that has led to the introduction of innovative products such as PET/MR.

PET and SPECT technologies, when compared to each other, have many differences; for instance PET radiopharmaceuticals emit positrons (two rays simultaneously), whereas SPECT radiopharmaceuticals emit gamma radiations, as PET has two electrons. At the same time, PET requires a higher number of cameras to capture them, thereby increasing the cost. Besides, PET radiopharmaceuticals require a cyclotron for production, escalating the cost further. On the other hand, the quality of image generated through PET is far better than that through SPECT.

The availability of radiopharmaceutical for SPECT (Technetium) is a major restraint, restricting the SPECT market. There is an ongoing research for developing technetium from accelerators, as the current methods are not able to meet the requirements. SPECT has the largest share in cardiology applications, whereas PET has dominance in oncology.